Dr Mike Israetel: ‘’ALMOST EVERY American Should Be On GLP-1s, Here’s Why!’’

What if vanity was actually the smart way into a longer, healthier life? This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. Their mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.

On this episode of Beyond Tomorrow, Dr. Mike Israetel breaks down what's actually happening in his own bloodstream: 5mg/week of tirzepatide year-round, plus retatrutide during fat-loss phases, and why he thinks “GLP-2” is a gray-market marketing term with no basis in real receptor biology. He walks through the non-weight-loss case for these drugs, reduced systemic and neural inflammation, better glucose control, emerging anti-cancer data, and a documented drop in addictive behaviors from gambling to alcohol to cigarettes, before getting honest about the tradeoffs: undernutrition, anhedonia, and a long-term data set that, by his own admission, will never be “complete enough” for some critics. From there the conversation moves into gray-market peptides, why Mike separates his own risk tolerance from what he'd recommend to the public, and why there currently isn't a single peptide he'd recommend for muscle growth despite the demand. The back half covers his real thesis: that appearance, not health, is the most reliable motivator most people actually respond to and that chasing it tends to produce the same outcomes doctors have failed for decades to sell through fear. Key Takeaways Mike takes tirzepatide (Zepbound/Mounjaro) year-round at 5mg/week and adds retatrutide during cutting phases, both well within studied dose ranges He argues most GLP-1 “anhedonia” is caloric-deficit anhedonia, not a direct drug effect, the same thing bodybuilders experience on any aggressive diet New aggregate mortality data shows older adults on GLP-1s die less than those who aren't, which he says partially answers the “but will it kill you later” question There is currently no peptide he'd recommend for muscle growth, a claim he says consistently disappoints people who ask His core argument: use appearance as the entry point (build muscle, lose fat, sleep better) and let the longevity benefits follow, rather than trying to motivate people with 30-years-out health outcomes Timestamps 00:00 Intro 00:10 Is GLP-1 a Bad Idea? 08:55 The Seatbelt Analogy for Drugs 10:30 The Peptide That's Not FDA-Approved Yet 11:30 Exactly What Mike Takes Every Week 13:59 Stacking Peptides: an N-of-1 Experiment 15:11 Why Mike Takes Anabolic Steroids 16:42 The Drug That Could Replace Steroids 18:48 Why Mike Takes Tirzepatide and Retatrutide 21:45 20-Year Life Extension 25:34 Mike's Full Daily Stack 30:47 The Looksmaxxing Trojan Horse 35:35 Sick Care vs. Health Care 38:14 Three Exercises You Can Do Today 40:36 Critiquing Brian Johnson's Protocol 43:31 Is There a One-Size-Fits-All Workout? 46:06 Zone 2 vs. Zone 5 Training 52:21 Why Most Biohacking Is a Waste of Money 54:01 Is HIIT Still the Rage? 57:09 Escaping Poverty, Fueling Success 01:04:53 Why People Take Extreme Measures to Look Good 01:08:24 Moving Past GLP-1 01:14:52 Everyone Will Look 22 by 2037 01:18:24 Would You Date a 90-Year-Old? 01:24:52 Beauty Standards in a Post-GLP-1 World 01:25:37 The Cybernetic Revolution 01:28:25 Living Forever in a Robot Body 01:36:29 Will AI Cause Human Extinction? 01:43:28 The Biggest Myth About Weight Loss 01:44:02 Rapid Fire Questions with Mike 01:48:06 Mike's Best Piece of Advice Connect with Mike: Website: rpstrength.com/ Facebook: facebook.com/michael.israetel Instagram: @drmikeisraetel X: @misraetel Connect with Julian Instagram: @thebeyondtomorrowpodcast / @juliankissa LinkedIn: julian-issa X: @juliankissa Website: www.beyondtomorrowpodcast.com Email: [email protected]